CORDIS
EU research results

CORDIS

English EN

Mimicking liver disease and regeneration in vitro for drug development and liver transplantation

Project information

Grant agreement ID: 742020

Status

Ongoing project

  • Start date

    1 September 2017

  • End date

    31 August 2022

Funded under:

H2020-EU.1.1.

  • Overall budget:

    € 2 413 449

  • EU contribution

    € 2 413 449

Hosted by:

KAROLINSKA INSTITUTET

Sweden

Objective

The liver is a vital organ for synthesis and detoxification. The most significant liver diseases are hepatitis, non alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver steatohepatitis (NASH), carcinoma and cirrhosis. An additional and important cause of liver injury is adverse drug reactions (ADRs). In particular NAFLD is the most common liver disease affecting between 20% and 44% of European adults and 43-70% of patients with type 2 diabetes, and is one prime cause for chronic and end-stage liver disease, such as cirrhosis and primary hepatocellular carcinoma.

This proposal is based on recent findings in the laboratory: The development of novel 3D spheroid system with chemically defined media allowing studies of chronic drug toxicity, relevant liver disease and liver function for 5 weeks in vitro, the finding of the role of miRNA in hepatocyte dedifferentiation and that hepatocytes during spheroid formation first de-differentiate but later in spheroids re-differentiate to an in vivo relevant phenotype. This forms the basis for the main objectives: i) to study diseased liver in vitro with identification of mechanisms, biomarkers and novel drug candidates for treatment of NAFLD and fibrosis, ii) evaluate drug toxicity sensitivity and mechanisms in diseased liver systems and iii) further develop methods for hepatocyte proliferation and regeneration in vitro for transplantation purposes, including genetic editing in cases of hepatocytes obtained from patients with genetically inherited liver diseases.

This work is carried out in close contact with the Hepatology unit at the Karolinska Hospital partly using resources at the Science for Life Laboratory at Karolinska. It is anticipated that the project can provide with novel mechanisms, biomarkers and new targets for treatment of liver disease as well as novel methods for clinically applicable liver regeneration without the use of stem cells or transformed cells.

Host institution

KAROLINSKA INSTITUTET

Address

Nobels Vag 5
17177 Stockholm

Sweden

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 413 449

Beneficiaries (1)

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 2 413 449

Project information

Grant agreement ID: 742020

Status

Ongoing project

  • Start date

    1 September 2017

  • End date

    31 August 2022

Funded under:

H2020-EU.1.1.

  • Overall budget:

    € 2 413 449

  • EU contribution

    € 2 413 449

Hosted by:

KAROLINSKA INSTITUTET

Sweden